Tocilizumab Plus a Short Prednisone Taper for GCA

Phase 4 Completed 30 enrolled Massachusetts General Hospital Roche-Genentech · collab

NaSingle-groupOpen-labelTreatment

Summary

This is an open-label pilot study of tocilizumab (TCZ) 162 mg weekly administered subcutaneously for 52 weeks in combination with 8 weeks of oral prednisone.

Timeline

Start: 2018-11-28
Primary completion: 2021-12-15
Completion: 2021-12-29

Publications

Unizony S, Matza MA, Jarvie A, O'Dea D, Fernandes AD, Stone JH. Treatment for giant cell arteritis with 8 weeks of prednisone in combination with tocilizumab: a single-arm, open-label, proof-of-concept study. Lancet Rheumatol. 2023 Dec;5(12):e736-e742. doi: 10.1016/S2665-9913(23)00265-5. Epub 2023 Nov 2.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Prednisone	Other / unclassified	20 mg	Oral
Subject	Prednisone	Other / unclassified	30 mg	Oral
Subject	Prednisone	Other / unclassified	40 mg	Oral
Subject	Prednisone	Other / unclassified	50 mg	Oral
Subject	Prednisone	Other / unclassified	60 mg	Oral
Subject	Tocilizumab	Monoclonal antibody	162 mg	Subcutaneous

Tocilizumab Plus a Short Prednisone Taper for GCA

Summary

Timeline

Publications

Drugs

Indications